scroll

Imugene (IMU)

ASX.IMU $0.20

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

ASX.IMU $0.20

20 MINUTE DELAYED

TODAY

8.33 %

1 YEAR RETURN

0.00%

VOLUME

20,200,371

DIV YIELD

PE RATIO

0.00

52 WEEK RANGE

0.13

0.63

ANALYSIS
OPINION
ACTION

ANALYSIS

Overview

SHARE PRICE ACTIVITY
Last (Price)	0.20
Change	0.02 (8.33)
Bid / Ask	0.20 - 0.20
Volume	20,200,371
Volume (3mths avg)	0
Turnover	3,946,789
Open	0.19
Day Range	0.18 - 0.21
VWAP	0.20
Prev Close	0.18
Last Trade	06.10 01/07 (AEST)

KEY INFORMATION
Sector	Healthcare
Shares Issued	4,885,986,365
NTA/Share	0.00
Last Dividend	0.00
Dividend Ex Date
Dividend Pay Date	29 MAR 2006

CURRENT ()
Revenue
EBITDA
Profit
Earnings Per Share (EPS)	0.00
Dividend Per Share (DPS)	0.00
Yield %	0.00
Market Cap	0.00
Price to Earnings Ratio (P/E)	0

TARGET PRICE FORECAST

ESTIMATES ()
Revenue	0.00
EBITDA	0.00
Profit	0.00
Earnings Per Share (EPS)	0.00
Dividend Per Share (DPS)	0.00

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00

OPINION

07/06/2022 09:41

Imugene Ltd (IMU) 17c

Health Biotech IMU manufacturers vaccines for gastric and breast cancer, it may look / feel like a “penny dreadful” trading at 17c but it does have a market cap of almost $1bn. This is a ‘risk on’ stock and is only likely to rally when the market feels confident enough to take on risk. Right now, it’s a coin toss to guess where it could end although the company has $100mn in cash and a number of promising trials...

22/03/2022 22:43

Imugene Ltd (IMU) 27c

IMU is a $1.6bn biotech that’s also more than halved over the last 6-months, its been a sorry tale across the sector. The business manufactures vaccines for gastric and breast cancers and we believe its recent collaboration with giant Merck & CO. is very encouraging providing a degree of confidence to accumulate into current weakness.

ACTION

IMU

UPDATED 07/06/2022 17:40

MM is neutral IMU – one for a high risk punt ~17c for the brave using stops below 15c

Add To Hit List

Read the opinion

IMU

UPDATED 22/03/2022 23:08

MM is neutral to positive IMU

Add To Hit List

Read the opinion

Business Summary

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.